Next Phase Newsletter

The corporate venture arm of an international healthcare company is currently making equity investments out of a $200 million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

The firm is primarily interested in companies that are of strategic interest to its parent company. These include innovative companies developing Therapeutics, Diagnostics, Medical Technology and Healthcare IT. In the therapeutics space the firm is highly interest in Gene therapy and is also open to companies working with small molecules and biologics. In the Medical Device Space the firm is generally open to all technology types including, Fluid Management Systems, Infusion Systems/IV Tubing, Software enabled devices, Home Care, Hospital Hardware and Drug Delivery Devices. For indications the firm is interested in areas of Oncology, Hematology, Immunology, Inflammation, and Pulmonology, Renal, Regenerative Medicine and Orphan Diseases. The firm is stage agnostic and will consider companies from the pre-clinical phase to those that already have products on the market. The firm is not interested in companies working with laboratory tools or technology that aids in the research/discovery process in the life science space.

The firm is looking for privately held companies and while they prefer companies to have a complete management team in place they are also open to working with companies to fill in gaps in management. The firm will lead investments although they generally prefer to co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A biotechnology-focused equity hedge fund based in Western US is looking to invest in therapeutics space. The investment size can vary greatly and the fund is very flexible depending on each company’s needs. The fund is geographically agnostic and looks to invest globally.

The firm is highly interested in biotech therapeutics. The fund is extremely opportunistic in terms of subsectors and indications and will consider companies at all stages of development. The fund recently invested in a European-based company developing small molecule therapeutics for CNS diseases and a US-based company developing therapeutics for oncology.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The fund will require either a board seat or observer status.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Venture Capital company formed in with offices in the Eastern and Western United States is looking to make equity investments ranging from approximately $3-$5 million initially and $10-$25 million over the investments lifetime. The firm looks for companies primarily in the United States, and some select opportunities in Europe. The firm plans to make between 1-5 investments over the next year.

The firm is interested in sectors of Biotech Therapeutics, Diagnostics, Medical Devices, Life Science Tools and Healthcare IT. In the Therapeutics space the firm is looking for both small molecule and biologics companies that are 1 year from entering clinical trials or later with a preference for companies that have in human data. The firm is generally open to all indications but is especially interested in areas of Oncology, Immunology and Orphan Diseases. For Medical Devices, Diagnostics and Life Science Tools the firm prefers to make later stage investments into companies that have significant in human data or have already been commercialized.

The firm is looking for experienced management teams and generally requires a board seat. The firm looks to take company through significant value inflection points acting as a very hand on investor. The firm almost always leads or co-leads investment rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm with bases in Hong Kong and the United States is primarily focused on healthcare investments with a particular interest in the life science space. The firm looks to make allocations ranging from $250,000 as the first round in a tranched financing structure to $20 million over the lifetime of the investment and depending on the financial needs of the company. The firm is actively seeking new investments and is open to review opportunities from around the globe.

Within the life science space the firm is interested in therapeutics, medical devices, and diagnostics. The firm is currently most interested in companies with some clinical data however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.

The firm is open to investing in both private and publically traded companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A hedge fund founded in 2001 and based in the eastern United States has raised a total of $250 million and is currently making investments out of it 4^th fund of $35 million. The firm looks to provide equity, convertible note and PIPE financings to mid and late stage companies in the life science space. Initial investments tend to range from $2-$3 million and the firm tends to invest anywhere from $3-$5 million over the lifetime of the investment.  The firm is looking for companies located in the US, Canada, Europe, China and Australia and makes approximately 4-5 investments each year.

The firm is looking for companies in sectors of Biotech Therapeutics, Diagnostics and Medical Technology. The firm is open to review almost all indications and subsectors but is particularly interested in areas of immunotherapy, cardiac devices, oncology, cell based therapies, small molecules, proteins, stem cells, and biogenetics. The firm is not interested in orthopedics. The firm is looking for companies that at least have clinical data, and will only evaluate certain preclinical stage assets if the pre-clinical data has some clinical viability.

The firm is looking for companies with experienced complete management teams in place. The firm is very interested in companies that are publically traded and will also invest in privately held companies. As the firm is a cross over investor they look to provide expansion capital and is not interested in company creation investments. The firm generally does not look to take a board seat but does act as a very hands-on investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Taiwan has USD 2.5 billion AUM and invests in companies of all stages, from early, expansion, to maturity stage. The firm invests in several sectors including healthcare. Currently, the firm is looking for investment opportunities with an exit timeline of 3-5 years. The firm is most interested in companies that are ready for IPO or M&A. The investment size varies depending on the stage of the company. The firm can allocate as USD 1 million up to USD 20 million or more, the firm invests in companies that are located in China, Taiwan, US, and Europe.

In healthcare, the firm is currently most interested in therapeutics. The firm is also looking at medical devices. For therapeutics, the firm looks for novel compounds and biologics that are either first-in-class or best-in-class. The firm is indication agnostic. In terms of stage of development, the firm is open as long as there is a concrete plan for an exit timeline of 3-5 years. For medical devices, the firm is generally opportunistic. The firm seeks devices that are innovative and disruptive.

The firm can both lead and co-invest with a syndicate. The firm generally request board of director’s representation following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture fund formed by a group of high net-worth individuals in China is currently seeking investment opportunities globally with a focus on China and US. Projects based in Canada, Germany, and Switzerland may also be considered. The fund pays close attention to investment opportunities from seed and early stage to growth stage. For seed and early stage projects, the fund makes investments in convertible notes and equity and is flexible on investment size. For growth stage projects, the fund makes equity investments of US$1-5 million in businesses with valuation of up to US$18-20 million. The fund typically syndicates with co-investors. The fund would like to partner with local investors in case of overseas investments.

The fund focuses on high-growth fields in medical devices, diagnostics, digital health, and consumer products and is gnostic to therapeutic areas.In diagnostics, the fund is interested in portable imaging devices, high-intensity ultrasound, point-of-care diagnostics, and molecular diagnostics. In digital health, the fund is interested in technologies that can be applicable to the Chinese market, such as connected devices, telemedicine, and patient-physician platforms. In consumer products, the fund in interested in OTC, nutrition, and dietary supplements that have proven efficacy and are on market.

The fund is looking to work with serial entrepreneurs from seed and early stages to growth stage to form complete and strong teams. The fund typically cooperates with local co-investors who play a supervisory role in overseas operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com